BCAL Diagnostics (ASX:BDX) Launches Avantect Multi-Cancer Early Detection Test in Australia
Get your Free Report on Top 5 ASX stocks for 2025
Australian healthcare company BCAL Diagnostics Limited (ASX: BDX) has announced on 23 September 2026 the phased domestic rollout of Avantect Multi Cancer early detection test, launching initially across Sydney and Melbourne ahead of a broader national release.
Avantect Multi-Cancer is a blood-based diagnosticΒ test designed to identify cancer associated signals across eight indications including lung, pancreatic, liver, ovarian, gastric, oesophageal, breast and colorectal while delivering a likely organ of origin signal to guide subsequent clinical evaluation.Β
In a large case control validation study, the liquid biopsy demonstrated an overall sensitivity of 56.2% and a specificity of 98.4% across all analysed cancers.Β
Patient blood samples collected through BCAL's Australian clinical infrastructure will be initially processed at ClearNote Healthβs CLIA certified and CAP accredited facility in the United States under an exclusive distribution agreement.
Company leadership underscored that the rollout reflects an industry wide transition toward non-invasive testing that improves early intervention access via General Practitioner and Specialist referrals. Management noted that an initial metro focused introduction allows the business to build critical operational insights across clinician adoption, patient demand, service delivery and pricing models before scaling nationwide.
The addition expands BCALβs commercial pipeline to four blood-based early detection offerings, directly complementing BREASTESTplus alongside dedicated tests for pancreatic and ovarian cancers. Over the long term, BCAL intends to shift all laboratory analysis for this portfolio to its dedicated Sydney clinical facility, driving scalable commercial operations across the region.
(Source: Company Announcements)
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether itβs appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
Feature News
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialRecent News
Genetic Signatures and Microba Agree to Commercial..
KTEK Aerosystems (ASX: KTK) Locks In Initial Defen..
Sultan Resources Secures Large-Scale Copper-Gold G..
Atlantic Lithium Clears Major Hurdle as Australian..
HeraMED Secures Commercial Rollout with Major US P..